tbuckley/cabot-search huggingface dataset:
Gemtuzumab Ozogamicin Plus Midostaurin in Combination with Standard Intensive Induction Therapy in Newly Diagnosed AML: Results from a Phase-I Study
Authors: Christoph Röllig, Christoph Schliemann, Jan-Henrik Mikesch, Lars Fransecky, Claudia D. Baldus, Björn-Niklas Heydrich, Maher Hanoun, Richard Noppeney, Sebastian Scholl, Ulf Schnetzke, Kerstin Schäfer-Eckart, Knut Wendelin, Martin Wermke, Manja Reimann, Frank Fiebig, Theresa Kretschmann, Friedrich Stoelzel, Nael Alakel, Martin Bornhäuser
Journal: Blood (2021)
Fibrinolytic Dysregulation Contributes to the Hypercoagulable State in Pulmonary Embolism Patients
Authors: Fakiha Siddiqui, Amir Darki, Emily Bontekoe, Yevgeniy Brailovsky, Omer Iqbal, Debra Hoppensteadt, Bulent Kantarcioglu, Alfonso J Tafur, Jawed Fareed
Journal: Blood (2021)
Genetic Dissection of Dyskeratosis Congenita-Causing Mutations in <i>TINF2</i> Using Human Pluripotent and Hematopoietic Stem Cell Models
Authors: Seunga Choo, Franziska K. Lorbeer, Samuel G. Regalado, Sarah B. Short, Shannon Wu, Gabrielle Rieser, Alison A. Bertuch, Dirk Hockemeyer
Journal: Blood (2021)
Impact of Age on Hospitalization and Readmission on Post Allogeneic Stem Cell Transplantation Outcome, Single Center Experience
Authors: Eshrak Al-Shaibani, Shiyi Chen, Wilson Lam, Arjun Law, Ivan Pasic, Fotios Michelis, Auro Viswabandya, Dennis Dong Hwan Kim, Armin Gerbitz, Jeffrey H. Lipton, Jonas Mattson, Rajat Kumar
Journal: Blood (2021)
Abstract 9151: Impact of Adult Congenital Cardiologists on the Care of Adults With Congenital Heart Disease
Authors: Katherine B Salciccioli, Hechuan Hou, Mark D Norris, Timothy B Cotts, Peter Sassalos, Ming-sing Si, Michael P Thompson
Journal: Circulation (2021)

Introduction: The adult congenital heart disease (ACHD) population has unique medical needs requiring specialized care. We evaluated the association between ACHD physician visits and guideline-adherent care in a cohort of insured ACHD patients. Methods: The Michigan Value Collaborative claims registry was queried for patients aged 18+ with ICD-10 codes for congenital heart disease (CHD) who had continuous insurance coverage from 1/2016 to 12/2020. Anatomic disease severity was stratified as simple or moderate/complex based on 2018 ACC/AHA ACHD guidelines. Patients were counted as seeing an ACHD physician if they had a single claim with a board-certified ACHD physician in Michigan during the 5-year period. Patient distance to nearest ACHD physician clinic was assessed based on home zip code. ACHD guideline adherence was defined as receiving one echocardiogram (all patients), two echocardiograms (moderate/complex disease), cross-sectional imaging (coarctation of the aorta), and/or liver imaging (single ventricle) during the 5-year period. Results: A total of 3,636 ACHD patients were identified with 17.9% (N=650) having moderate/complex CHD. ACHD physicians saw 3.4% (N=103/2986) of patients with simple disease and 23.4% (N=152/650) with moderate/complex disease. Most patients lived &lt;50 miles from an ACHD physician - 87.5% of those who saw ACHD and 84.2% of those who did not - with similar distance distributions between groups (p=0.13). Patients who saw an ACHD physician were significantly more likely to have guideline-recommended imaging ( Figure 1 ). Conclusion: Being seen by a board-certified ACHD physician was associated with greater adherence to guideline-recommended care in this cohort of insured ACHD patients. However, the vast majority of patients did not see an ACHD physician despite having continuous insurance coverage and geographic accessibility. More work is needed to identify the barriers to obtaining ACHD-specific care.
Does Fibrin Structure Contribute to the Increased Risk of Thrombosis in COVID-19 ICU Patients?
Authors: Judith Juliana De Vries, Chantal Visser, Lotte Geers, Johan A. Slotman, Henrik Endeman, Marieke J.H.A. Kruip, Moniek P.M. de Maat, The Dutch COVID & Thrombosis Coalition
Journal: Blood (2021)
Estimation of DAPT Study Treatment Effects in Contemporary Clinical Practice: Findings From the EXTEND-DAPT Study
Authors: Neel M. Butala, Kamil F. Faridi, Hector Tamez, Jordan B. Strom, Yang Song, Changyu Shen, Eric A. Secemsky, Laura Mauri, Dean J. Kereiakes, Jeptha P. Curtis, C. Michael Gibson, Robert W. Yeh
Journal: Circulation (2021)

Differences in patient characteristics, changes in treatment algorithms, and advances in medical technology could each influence the applicability of older randomized trial results to contemporary clinical practice. The DAPT Study (Dual Antiplatelet Therapy) found that longer-duration DAPT decreased ischemic events at the expense of greater bleeding, but subsequent evolution in stent technology and clinical practice may attenuate the benefit of prolonged DAPT in a contemporary population. We evaluated whether the DAPT Study population is different from a contemporary population of US patients receiving percutaneous coronary intervention and estimated the treatment effect of extended-duration antiplatelet therapy after percutaneous coronary intervention in this more contemporary cohort.
Assessment and management of retinopathy of prematurity in the era of anti-vascular endothelial growth factor (VEGF)
Authors: Andrew SH. Tsai, Hung-Da Chou, Xiao Chun Ling, Tala Al-Khaled, Nita Valikodath, Emily Cole, Vivien L. Yap, Michael F. Chiang, R.V. Paul Chan, Wei-Chi Wu
Journal: Progress in Retinal and Eye Research (2021)
Synergistic Role of Leukemic and Non-Leukemic Immune Repertoires in CD8+ T-Cell Large Granular Lymphocytic Leukemia As Identified By Single-Cell Transcriptomics
Authors: Dipabarna Bhattacharya, Jani Huuhtanen, Matti Kankainen, Tapio Lönnberg, Cassandra M Kerr, Jason Theodoropoulos, Hanna Rajala, Tiina Kasanen, Till Braun, Antonella Teramo, Renato Zambello, Marco Herling, Fumihiro Ishida, Toru Kawakami, Marko Salmi, Thomas P. Loughran, Jaroslaw P. Maciejewski, Harri Lähdesmäki, Tiina Kelkka, Satu Mustjoki
Journal: Blood (2021)
Pyrotinib in Patients with HER2-Amplified Advanced Non–Small Cell Lung Cancer: A Prospective, Multicenter, Single-Arm Trial
Authors: Zhengbo Song, Dongqing Lv, Shi-Qing Chen, Jianjin Huang, Yuping Li, Shenpeng Ying, Xiaoyu Wu, Feng Hua, Wenxian Wang, Chunwei Xu, Ting Bei, Chan Gao, Zhijian Sun, Yiping Zhang, Shun Lu
Journal: Clinical Cancer Research (2021)

Abstract Purpose: In this study, we aimed to evaluate the efficacy and safety of pyrotinib, a pan-HER inhibitor, in patients with HER2-amplified non–small cell lung cancer (NSCLC). Patients and Methods: In this prospective, multicenter, single-arm trial (ChiCTR1800020262), patients with advanced NSCLC with HER2 amplification, as determined by next-generation sequencing, were enrolled and administered pyrotinib orally at 400 mg per day. The primary endpoint was 6-month progression-free survival (PFS) rate. Other endpoints included objective response rate (ORR), disease control rate (DCR), PFS, overall survival (OS), and safety. Results: The enrolled cohort included 27 patients with HER2 amplification. The 6-month PFS rate was 51.9% [95% confidence interval (CI), 34.0–69.3]. The median PFS (mPFS) was 6.3 months (95% CI, 3.0–9.6 months), and median OS was 12.5 months (95% CI, 8.2–16.8 months). Pyrotinib elicited a confirmed ORR of 22.2% (95% CI, 10.6%−40.8%). Patients administered pyrotinib as first-line treatment achieved an mPFS of 12.4 months. Moreover, 30.8% of the patients who had progressed on EGFR tyrosine kinase inhibitor (TKI) responded to pyrotinib. Patients with brain metastases had an ORR of 40%. Treatment-related adverse events (TRAE) occurred in all patients (grade 3, 22.2%), but no grade 4 or higher TRAEs were documented. Diarrhea was the most frequent TRAE (all, 92.6%; grade 3, 7.4%). Loss of HER2 amplification was detected upon disease progression. Conclusions: Pyrotinib provided antitumor efficacy with a manageable safety profile in HER2-amplified patients with NSCLC.
Aerobic exercise capacity in long-term survivors of critical illness: secondary analysis of the post-EPaNIC follow-up study
Authors: Nathalie Van Aerde, Philippe Meersseman, Yves Debaveye, Alexander Wilmer, Michael P. Casaer, Jan Gunst, Joost Wauters, Pieter J. Wouters, Kaatje Goetschalckx, Rik Gosselink, Greet Van den Berghe, Greet Hermans
Journal: Intensive Care Medicine (2021)
Trial in Progress: Phase 1b Bridging Study of the Pharmacokinetics (PK), Safety, and Efficacy of Orally Administered Olverembatinib (HQP1351) in Patients with Refractory Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph⁺ ALL)
Authors: Elias J. Jabbour, Hagop Kantarjian, Ghayas C. Issa, Joseph Thaddeus Beck, Rebecca B. Klisovic, Sudipto Mukherjee, Vivian G. Oehler, Zi Chen, Ming Lu, Tommy Fu, Lixin Jiang, Yifan Zhai, Dajun Yang
Journal: Blood (2021)
TAMI-06. TUMOR CELL-DERIVED CYTOKINE EXPRESSION CHANGES ASSOCIATED WITH BRAIN METASTASIS IN A SYNGENEIC MOUSE MODEL OF BREAST CANCER
Authors: Ramin Morshed, Alexander Haddad, Saket Jain, Sabraj Gill, Jordan Spatz, Manish K Aghi
Journal: Neuro-Oncology (2021)

Abstract Breast cancer is the most common malignancy in women in the United States, and brain metastases occur in almost a third of patients with metastatic dissemination. Immunoediting is a critical component of metastatic tumor cell elimination, and tumor clones that develop immune-escape mechanisms are associated with progression and metastatic dissemination. We hypothesized that breast cancer brain metastatic cells harbor immunomodulatory cytokine expression changes that promote an immunosuppressive environment to avoid immune cell-mediated elimination. To study this, a syngeneic mouse model of metastatic breast cancer was used. A brain metastatic line derived from the 4T1 breast cancer parental cell line was created by serially selecting brain metastatic populations of cells after intracardiac injection (4T1 BrM). A gene-expression analysis using an 800-gene cancer immunology-specific microarray panel was performed comparing the 4T1 parental and 4T1 BrM lines. 4T1 BrM cells demonstrate gene expression changes promoting immunosuppression including significant upregulation of IL18 and Lgals9 (Galectin-9) and downregulation of CD40, IL2rg, CCL2, and EOMES. When compared to 4T1 parental lines, the 4T1 BrM line demonstrated decreased expression of CCL2 and increased expression of GM-CSF on a cytokine array, corresponding to results obtained from gene expression analysis. These results suggest tumor-intrinsic cytokine expression changes that may mediate an immunosuppressive environment.
Detection of <i>CSRP2</i> Transcript Levels By Real-Time Quantitative PCR May be a Useful Tool for Monitoring Minimal Residual Disease in B-Cell ALL
Authors: Lei-Ming Cao, Li-Xin Wu, Ming-Yue Zhao, Ya-Lan Zhou, Jin-Lan Li, Qiu-Yu Sun, Hao Jiang, Jiang Qian, Lan-Ping Xu, Xiao-Hui Zhang, Kai-Yan Liu, Xiao-Jun Huang, Guo-Rui Ruan
Journal: Blood (2021)
Community control strategies for scabies: A cluster randomised noninferiority trial
Authors: Myra Hardy, Josaia Samuela, Mike Kama, Meciusela Tuicakau, Lucia Romani, Margot J. Whitfeld, Christopher L. King, Gary J. Weil, Tibor Schuster, Anneke C. Grobler, Daniel Engelman, Leanne J. Robinson, John M. Kaldor, Andrew C. Steer
Journal: PLoS Medicine (2021)

Background Scabies is a neglected tropical disease hyperendemic to many low- and middle-income countries. Scabies can be successfully controlled using mass drug administration (MDA) using 2 doses of ivermectin-based treatment. If effective, a strategy of 1-dose ivermectin-based MDA would have substantial advantages for implementing MDA for scabies at large scale. Methods and findings We did a cluster randomised, noninferiority, open-label, 3-group unblinded study comparing the effectiveness of control strategies on community prevalence of scabies at 12 months. All residents from 35 villages on 2 Fijian islands were eligible to participate. Villages were randomised 1:1:1 to 2-dose ivermectin-based MDA (IVM-2), 1-dose ivermectin-based MDA (IVM-1), or screen and treat with topical permethrin 5% for individuals with scabies and their household contacts (SAT). All groups also received diethylcarbamazine and albendazole for lymphatic filariasis control. For IVM-2 and IVM-1, oral ivermectin was dosed at 200 μg/kg and when contraindicated substituted with permethrin. We designated a noninferiority margin of 5%. We enrolled 3,812 participants at baseline (July to November 2017) from the 35 villages with median village size of 108 (range 18 to 298). Age and sex of participants were representative of the population with 51.6% male and median age of 25 years (interquartile range 10 to 47). We enrolled 3,898 at 12 months (July to November 2018). At baseline, scabies prevalence was similar in all groups: IVM-2: 11.7% (95% confidence interval (CI) 8.5 to 16.0); IVM-1: 15.2% (95% CI 9.4 to 23.8); SAT: 13.6% (95% CI 7.9 to 22.4). At 12 months, scabies decreased substantially in all groups: IVM-2: 1.3% (95% CI 0.6 to 2.5); IVM-1: 2.7% (95% CI 1.1 to 6.5); SAT: 1.1% (95% CI 0.6 to 2.0). The risk difference in scabies prevalence at 12 months between the IVM-1 and IVM-2 groups was 1.2% (95% CI −0.2 to 2.7, p = 0.10). Limitations of the study included the method of scabies diagnosis by nonexperts, a lower baseline prevalence than anticipated, and the addition of diethylcarbamazine and albendazole to scabies treatment. Conclusions All 3 strategies substantially reduced prevalence. One-dose was noninferior to 2-dose ivermectin-based MDA, as was a screen and treat approach, for community control of scabies. Further trials comparing these approaches in varied settings are warranted to inform global scabies control strategies. Trial registration Clinitrials.gov NCT03177993 and ANZCTR N12617000738325 .
The Loss of ALDH9A1 Is a Significant Source of Endogenous DNA Damage Which May be Reversed By the Inhibition of Polyamine Transport System
Authors: Moonjung Jung, Isaac Ilyashov, Danielle Keahi, Tom Wiley, Sunandini Sridhar, Audrey Goldfarb, Haruna B Choijilsuren, Yeji Park, Ryan White, Raymond Noonan, Thomas S Carroll, Frank X. Donovan, Francis P. Lach, Arleen D. Auerbach, Settara C. Chandrasekharappa, Agata Smogorzewska
Journal: Blood (2021)
Genomic Characterization of <i>in Vitro</i> Acquired-Resistance to Proteasome Inhibitors
Authors: Hugues De Boussac, Alboukadel Kassambara, Amelie Machura, Djamila Chemlal, Claire Gourzones, Guilhem Requirand, Nicolas Robert, Laure Vincent, Charles Herbaux, Angélique Bruyer, Jerome Moreaux
Journal: Blood (2021)
Safety and Preliminary Efficacy from the Expansion Cohort of a Phase 1/2 Study of Venetoclax Plus Daratumumab and Dexamethasone Vs Daratumumab Plus Bortezomib and Dexamethasone in Patients with t(11;14) Relapsed/Refractory Multiple Myeloma
Authors: Jonathan L. Kaufman, Hang Quach, Rachid Baz, Annette J. Vangsted, Shir-Jing Ho, Simon J Harrison, Torben Plesner, Philippe Moreau, Simon D. Gibbs, Eva Medvedova, Vasudha Sehgal, Kingston Kang, Jeremy A. Ross, L. Leanne Lash-Fleming, Yan Luo, Nizar J. Bahlis
Journal: Blood (2021)
Abstract 9370: Myocardial Tissue Characterization of Pediatric Patients With Duchenne Muscular Dystrophy
Authors: Sudeep Sunthankar, Kristen George-Durrett, Kim Crum, Larry W Markham, Jonathan H Soslow
Journal: Circulation (2021)

Introduction: Cardiomyopathy (CM) is the leading cause of death in Duchenne muscular dystrophy (DMD). Cardiac magnetic resonance (CMR) parametric mapping sequences, Native T1, T2, and extracellular volume (ECV), can offer insights into disease pathophysiology. The objective of this abstract was to leverage parametric mapping sequences to define the tissue characteristics of DMD CM progression. We hypothesized DMD subjects could be categorized based on fibrosis, myocardial edema, and fat infiltration. Methods: DMD patients (n=52; median 12.1 years) underwent CMR including T1, T2, and ECV at the base, mid, and apex. Categories were defined as normal, early fibrosis (normal ECV, high T1, normal T2), fibrosis (high ECV, normal or high T1, normal T2), edema (normal or high ECV, normal or high T1, high T2), fat (normal ECV, low T1, high T2) or fibrofatty (high ECV, normal or low T1, high T2). Statistical analysis included Chi-square, Wilcoxon rank sum, Wilcoxon signed rank, and Spearman’s rho. Results: Median left ventricular ejection fraction (LVEF) was 59% and 15 (29%) had LVEF &lt; 55%; 18 subjects (35%) had normal LVEF and no late gadolinium enhancement. These subjects were younger (10.2 years [8.4,11.6] vs 14.7 [11.5,17.8], p&lt;0.001). Native T1 was elevated in at least one slice in 42 (81%). Patients with high T2 at any slice (n=13) were older (p=0.009) and had lower LVEF (p=0.009) compared with normal T2 (n=39). The most common stratifications (Figure 1) were early fibrosis (n=14) and fibrosis (n=21). Of the 13 with high T2, 9 were categorized as edema, 2 as fibrofatty, and 2 as fat. T2 at the base, mid, and apex increased from first to second CMR (all p&lt;0.05) and T2 at mid and apex correlated with age (rho=0.2 and rho=0.38, p&lt;0.05). Conclusion: Myocardial fibrosis is common in DMD. CM progresses with age and higher T2 suggesting fatty/fibrofatty infiltration. CMR parametric mapping sequences offer insights into disease pathophysiology, which should drive therapeutic innovation.
Methionine synthase is essential for cancer cell proliferation in physiological folate environments
Authors: Mark R. Sullivan, Alicia M. Darnell, Montana F. Reilly, Tenzin Kunchok, Lena Joesch-Cohen, Daniel Rosenberg, Ahmed Ali, Matthew G. Rees, Jennifer A. Roth, Caroline A. Lewis, Matthew G. Vander Heiden
Journal: Nature Metabolism (2021)
EUS-guided gastrojejunostomy in the presence of ascites
Authors: Mehdi Mohamadnejad
Journal: Endoscopy (2021)

EUS-guided gastroenterostomy (EUS-GE) is a novel procedure to palliate malignant gastric outlet obstruction (GOO). Retrospective studies reported a higher rate of clinical success with EUS-GE compared to duodenal stenting [1]. The presence of ascites is often considered a contraindication for this procedure because of concern over the development of anastomotic dehiscence or peritonitis [2] [3].
Real-World Applicability of Commercial Chimeric Antigen Receptor T Cell Therapy Among Older Adults with Relapsed and/or Refractory Multiple Myeloma
Authors: Smith Giri, Susan Bal, Kelly N. Godby, Gayathri Ravi, Deanna Clark, Clare Ubersax, Abigail Cooley, Priscila White, Sunil Rangarajan, Grant R Williams, Luciano J. Costa
Journal: Blood (2021)
Childhood Obesity Interventions—Going Beyond the Individual
Authors: Izzuddin M. Aris, Jason P. Block
Journal: JAMA Pediatrics (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Single-Cell Proteogenomic Sequencing Allows Early Detection of Relapse Clone with CN-LOH at <i>FLT3</i>-ITD Locus from Initial Diagnosis in AML
Authors: Taehyung Kim, Hyewon Lee, Jose-Mario Capo-Chichi, Myung Hee Chang, Young Seok Yoo, Gurbaksh Basi, Troy Ketela, Adam C. Smith, Anne Tierens, Mark D. Minden, Zhaolei Zhang, Dennis Dong Hwan Kim
Journal: Blood (2021)
Single Cell Analyses Reveal a Non-Canonical EZH2 Activity As a Main Driver of Retinoic Acid Resistance in PLZF/Rara Leukemia
Authors: Mathilde Poplineau, Nadine Platet, Adrien Mazuel, Léonard Hérault, Shuhei Koide, Wakako Kuribayashi, Nadine Carbuccia, Lia N'Guyen, Julien Vernerey, Motohiko Oshima, Daniel Birnbaum, Christophe Lachaud, Atsushi Iwama, Estelle Duprez
Journal: Blood (2021)
Early, Deep, and Durable Responses, and Low Rates of Cytokine Release Syndrome with REGN5458, a BCMAxCD3 Bispecific Monoclonal Antibody, in a Phase 1/2 First-in-Human Study in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Authors: Jeffrey A. Zonder, Joshua Richter, Naresh Bumma, Jason Brayer, James E Hoffman, William I. Bensinger, Ka Lung Wu, Linzhi Xu, Dhruti Chokshi, Anita Boyapati, Manish Sharma, Karen Rodriguez Lorenc, Glenn S Kroog, Madhav V Dhodapkar, Suzanne Lentzsch, Dennis Cooper, Sundar Jagannath
Journal: Blood (2021)
Final Overall Survival Results from BELLINI, a Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma
Authors: Shaji Kumar, Simon J Harrison, Michele Cavo, Javier de la Rubia, Rakesh Popat, Cristina J. Gasparetto, Vania Hungria, Hans Salwender, Kenshi Suzuki, Inho Kim, Maika Onishi, Grace Ku, Rajvineeth Kumar Pothacamury, Vasudha Sehgal, Abdullah A. Masud, Jeremy A. Ross, Edyta Dobkowska, Philippe Moreau
Journal: Blood (2021)
Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial
Authors: Aparna R. Parikh, Annamaria Szabolcs, Jill N. Allen, Jeffrey W. Clark, Jennifer Y. Wo, Michael Raabe, Hannah Thel, David Hoyos, Arnav Mehta, Sanya Arshad, David J. Lieb, Lorraine C. Drapek, Lawrence S. Blaszkowsky, Bruce J. Giantonio, Colin D. Weekes, Andrew X. Zhu, Lipika Goyal, Ryan D. Nipp, Jon S. Dubois, Emily E. Van Seventer, Bronwen E. Foreman, Lauren E. Matlack, Leilana Ly, Jessica A. Meurer, Nir Hacohen, David P. Ryan, Beow Y. Yeap, Ryan B. Corcoran, Benjamin D. Greenbaum, David T. Ting, Theodore S. Hong
Journal: Nature Cancer (2021)
Rusfertide (PTG-300) Induction Therapy Rapidly Achieves Hematocrit Control in Polycythemia Vera Patients without the Need for Therapeutic Phlebotomy
Authors: Yelena Ginzburg, Kamini Kirubamoorthy, Sinari Salleh, Sung-Eun Lee, Jae Hoon Lee, Veena Selvaratnam, Suneel K Gupta, Frank Valone, Sarita Khanna, Nishit B Modi, Ronald Hoffman, Lee Ping Chew
Journal: Blood (2021)
A Phase 1 Study to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Lisaftoclax (APG-2575), a Novel BCL-2 Inhibitor (BCL-2i), in Patients (pts) with Certain Relapsed or Refractory (R/R) Hematologic Malignancies (HMs)
Authors: Mingyuan Sun, Junyuan Qi, Zi Chen, Hongli Zhang, Yongping Song, Aizong Shen, Huilan Liu, Jianying Huang, Fuling Zhou, Jie Jin, Ming Lu, Mohammad Ahmad, Lichuang Men, Wan Cen, Dajun Yang, Jianxiang Wang, Yifan Zhai
Journal: Blood (2021)